What Is Telehealth Addiction Treatment?

Telehealth addiction treatment includes 5 sequential components: video intake assessment, individual telehealth sessions, group telehealth sessions, medication management, and care coordination. Each component mirrors its in-person equivalent in clinical structure while using live video as the delivery format. The following are the 5 components:

1. Video intake assessment — a licensed clinician conducts the initial evaluation over live video, covering substance use history, DSM-5-TR criteria for substance use disorder, mental health screening, and confirmation of the appropriateness criteria for telehealth delivery.
2. Individual telehealth sessions — one-on-one therapy delivered live, scheduled 1 to 3 times weekly depending on the client's individualized treatment plan.
3. Group telehealth sessions — group therapy delivered live over a secure video platform, scheduled 3 to 5 times weekly to meet weekly clinical-hour requirements.
4. Medication management — prescriber visits for medications including buprenorphine, conducted via live video. DEA telemedicine flexibilities permit buprenorphine initiation without a prior in-person exam in defined circumstances.
5. Care coordination — case management tracks session attendance, coordinates insurance authorization, and manages transitions to a higher or lower level of care as clinical status changes.

Ascend Recovery's telehealth program delivers this 5-component structure at the intensive outpatient and outpatient levels of care.

Telehealth IOP delivers the same 9 to 19 weekly clinical hours as in-person IOP, using live video for group and individual sessions instead of a physical treatment setting. The weekly-hour requirement does not change with the delivery modality. Telehealth is a delivery modality layered onto an existing ASAM level of care — intensive outpatient program (IOP) or standard outpatient — rather than a distinct ASAM level itself.

Standard outpatient rehab delivers 1 to 2 sessions per week regardless of whether those sessions occur by live video or in person. The clinical content, session length, and required weekly hours at each ASAM level remain constant across both delivery formats — only the format of the group and individual sessions changes. Insurance coverage and out-of-pocket cost for telehealth sessions follow the same structure as in-person sessions at the same ASAM level.

Telehealth addiction treatment carries two federal privacy shields, not one: HIPAA governs all protected health information, and 42 CFR Part 2 adds a stricter layer that specifically governs substance use disorder records and generally bars disclosure without the patient's explicit written consent. Most "is telehealth private?" explanations blur this second shield into generic HIPAA language and miss the distinction.

HIPAA sets the baseline for every telehealth session — encrypted, access-controlled platforms, secured records, and limits on who may view protected health information. 42 CFR Part 2 was written specifically for substance use disorder treatment records held by federally assisted programs, and it is stricter than HIPAA in one decisive way: those records generally cannot be used or disclosed, even to another treating provider or a payer, without the patient's signed, specific consent, and they carry heightened protection against use in legal proceedings.

Florida Statute 456.47 governs who may deliver that video care to a Florida resident. The treating clinician must hold an active Florida license, and an out-of-state provider who wants to treat Florida patients by telehealth must register with the state, maintain a Florida-based registered agent and matching professional liability coverage, and is prohibited from opening a physical office or delivering any in-person care in Florida. Ascend Recovery's clinicians hold active Florida licenses and deliver telehealth under this statute. The private-space requirement checked at intake protects this confidentiality at the client's end. These confidentiality protections carry directly into how telehealth prescribers manage medication, including buprenorphine for opioid use disorder.

The DEA and HHS finalized a permanent pathway on January 17, 2025, that lets a qualified clinician prescribe buprenorphine for opioid use disorder after a single telemedicine encounter, with no prior in-person exam, an initial 6-month supply of Schedule III–V medication, and an audio-only option for patients without video. This closed a long-standing gap that had generally required an in-person evaluation before any controlled-substance prescription.

Under the rule, a prescriber evaluates the patient over live audio-video, confirms the DSM-5-TR criteria for opioid use disorder, and initiates buprenorphine using standard induction protocols — dispensing up to a 6-month initial supply through telemedicine. For patients who lack video access, the audio-only allowance means a phone encounter can still start treatment. Separately, the broader controlled-substance telemedicine flexibilities were extended through December 31, 2026, averting the "telemedicine cliff" that would otherwise have forced patients back to in-person visits to keep their prescriptions.

The evidence on telehealth-delivered addiction care is specific about where it is strongest. A 2021 review in Psychiatric Services found telehealth as effective as — but not more effective than — in-person care on retention, therapeutic alliance, and substance use outcomes. Clinicians reported the most confidence in individual counseling delivered by video, and were less certain that telehealth-delivered group counseling, medication management, and intake assessments match in-person outcomes as closely. This is why Suboxone (buprenorphine) treatment and one-on-one therapy transfer cleanly to video, while intake and group sessions are structured deliberately to preserve clinical quality. What that evidence means for cost is that a telehealth week is priced the same as its in-person equivalent.

Telehealth addiction treatment costs the same as in-person care at the same ASAM level, because the Mental Health Parity and Addiction Equity Act (MHPAEA) requires insurance plans that cover behavioral health to apply no greater restrictions to substance use disorder treatment — including telehealth-delivered treatment — than to medical and surgical benefits. Commercial insurance plans and Medicaid typically cover telehealth IOP and outpatient sessions under the same benefit structure applied to in-person sessions at the equivalent level of care. Out-of-pocket cost for a client with active insurance is generally limited to the plan's standard copay or coinsurance per session, consistent with in-person treatment costs at the same ASAM level.

Verify insurance coverage to confirm telehealth benefits before scheduling an intake assessment.

Starting telehealth addiction treatment involves 5 steps: insurance verification, a telehealth intake assessment, a device and private-space check, scheduling the first live video session, and beginning treatment the same week. The following are the 5 steps in sequence:

1. Insurance verification — confirm telehealth benefits and coverage at the appropriate ASAM level before intake.
2. Telehealth intake assessment — a licensed clinician conducts the initial evaluation over live video to confirm appropriateness for telehealth delivery.
3. Device, internet, and private-space check — confirm the client has a device, internet connection, and private location capable of sustaining a live video session.
4. Scheduling the first live video session — the client is matched to an individual therapist and a group cohort based on the treatment plan established at intake.
5. Same-week start — same-week start is typical once insurance verification and intake are complete.

Clients who begin treatment through this sequence receive the same clinical modalities, weekly-hour structure, and outcome expectations as clients in in-person IOP and outpatient care.

Clients considering telehealth addiction treatment can confirm insurance benefits and schedule a live-video intake assessment to determine appropriateness and begin treatment the same week.